GNAO1 R243H Stably Expressing Immortalized Human Mammary Epithelial Cell Line

Unit

1×10⁶ cells / 1 ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Mammary

Organism

Human (H. sapiens)

Donor History

Female

Growth Properties

Adherent

,

epithelial-like

Growth Conditions

Use of PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. PriGrow IV (TM004) + 50 µM fresh ascorbic acid + 2 nM estradiol + 1 µg/ml insulin + 2.8 µM hydrocortisone + 0.1 mM ethanolamine + 0.1 mM L-glutamine (G275)

,

15 nM sodium selenite + 1 ng/ml cholera toxin + 12.5 ng/ml hEGF (Z100139) + 10% fetal bovine serum (TM999) or 35 µg/ml bovine pituitary extract (Hammond) + 1% Penicillin/Streptomycin Solution (G255). Adjust media to pH 7.4 before use

,

37.0°C

,

5% CO₂

Immortalization Method
Full Information

https://www.abmgood.com/gnao1-r243h-stably-expressing-immortalized-human-mammary-epithelial-cell-line.html

Katalogové číslo: T6202 Kategorie: ,
Popis

GNAO1 R243H Stably Expressing Immortalized Human Mammary Epithelial Cell line expresses GNAO1, the protein of which represent the alpha subunit of the G0 heterotrimeric G-protein signal-transducing complex and is partially responsible for smooth muscle contraction and depressing neuronal activity. This genes role is to inhibit adenylate cyclase , open K -channels (via β/γ subunits), and close Ca2 -channels. This particular cell line expresses the Arginine243 → Histidine (R243H) mutation of GNAO1, which has been identified in breast carcinomas and is known to promote oncogenesis when introduced into cells. The oncogenic R234H mutation renders Gαo constitutively active by accelerating the rate of nucleotide exchange, which enhances signaling pathways that are associated with neoplasmic transformation. This cell line was made using retrovirus transduction. It carries flag tag and expresses GFP.

O značce
Applied Biological Materials (abm) je jedním z našich klíčových dodavatelů pro biotechnologický průmysl. Společnost byla založena v roce 2004 a již více než deset let podporuje vědecké objevy v oblasti přírodních věd a vývoje léčiv. Její sídlo se nachází ve Vancouveru v Kanadě. ABM je pro nás neocenitelným partnerem zejména v  oblasti dodávek buněčných kultur, genových a virových vektorů, produktů pro molekulární biologii a PCR, nástrojů pro technologie CRISPR a RNAi, protilátek i základních reagencií pro molekulárně genetické procesy.